Stifel Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS) following in-line Q4
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $10.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
